Achieve Life Sciences financials
$7.69−0.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$18.5M | -$10.5M | -$15.1M | -$14.7M | -$12.7M | -$12.9M | -$12.8M | -$12.5M | -$8.4M | -$6.0M | -$4.9M | -$6.6M |
| Net income | -$74.8M | -$10.2M | -$14.7M | -$14.4M | -$12.7M | -$12.8M | -$12.4M | -$12.5M | -$8.5M | -$6.5M | -$5.5M | -$7.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.80 | $-0.19 | $-0.27 | $-0.28 | $-0.37 | $-0.37 | $-0.36 | $-0.36 | $-0.25 | $-0.26 | $-0.26 | $-0.34 |
| EBITDA | -$18.4M | -$10.4M | -$14.7M | -$14.6M | -$12.6M | -$12.8M | -$12.1M | -$12.4M | -$8.4M | -$5.9M | -$4.4M | -$6.5M |
| Operating cash flow | -$10.8M | -$6.9M | -$18.0M | -$11.3M | -$9.1M | -$11.1M | -$9.2M | -$10.4M | -$4.9M | -$5.3M | -$4.4M | -$5.1M |
| Free cash flow | -$10.8M | -$6.9M | -$18.0M | -$11.3M | -$9.1M | -$11.1M | -$9.2M | -$10.4M | -$4.9M | -$5.3M | -$4.4M | -$5.2M |
| Diluted shares | 93.5M | 53.4M | 54.0M | 51.0M | 34.7M | 34.7M | 34.6M | 34.4M | 34.3M | 25.0M | 21.2M | 21.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.0M | $28.1M | $20.9M | $31.9M | $51.9M | $13.0M |
| Short-term investments | $139.3M | $1.2M | $15.5M | $16.2M | $3.5M | $10.2M |
| Total debt | $14.9M | $14.9M | $14.9M | $9.9M | $9.9M | $9.9M |
| Total assets | $190.4M | $33.1M | $41.8M | $52.0M | $58.9M | $27.4M |
| Total liabilities | $205.1M | $22.4M | $20.3M | $18.4M | $17.3M | $17.1M |
| Shareholders' equity | -$14.7M | $10.7M | $21.5M | $33.6M | $41.7M | $10.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology